US biotech developing oral KCC2-targeting neuromedicines for epilepsy and pain.
| Date | Round | Amount |
|---|---|---|
| Oct 2024 | Series A Axonis Therapeutics raised $115m in Series A financing co-led by Cormorant Asset Management and venBio Partners to advance its lead neuromedicine candidate AXN-027. | $115M |
| Jul 2021 | Seed Axonis Therapeutics, co-founded by UCC graduates and based in Cambridge, Massachusetts, raised $5m led by Alexandria Venture Investments to develop therapies for neurological disorders. | $5M |